The aim of this trial was to compare the efficacy and safety of extended-release ciprofloxacin (CIPRO XR) versus the immediate-release formulation (CIPRO IR) in the treatment of complicated urinary tract infections (UTIs). 212 patients were randomized to CIPRO XR 1,000 mg tablet once daily or CIPROXIN IR 500 mg tablet twice daily. Treatment efficacy was evaluated by bacteriological outcome. Safety was measured by recording adverse events. The rate of bacteriological eradication was 83% in the CIPRO XR group and 75% in the CIPRO IR. the overall incidence of adverse events reported was higher in the CIPRO IR group. The authors conclude that CIPRO XR is a safe and effective treatment for complicated UTIs. Although the limited data available do not consent to support a statistically superior efficacy or safety compared to CIPRO IR, a trend in favor of CIPRO XR is clearly evident in all efficacy and safety variables. CIPRO XR is associated with reduced frequencies of drug-related adverse events compared to CIPRO IR.

MIRONE, V., FUSCO, F., TAGLIALATELA, D., VERZE, P., DI VITO, C., LOTTI, T., et al. (2009). Efficacy and safety of Cyprofloxacin XR 1000mg once daily versus Ciprofloxacin 500mg twice daily in the treatment of complicated urinary tract infections. JOURNAL OF CHEMOTHERAPY, 21(6), 651-660.

Efficacy and safety of Cyprofloxacin XR 1000mg once daily versus Ciprofloxacin 500mg twice daily in the treatment of complicated urinary tract infections

PAVONE, Carlo
2009-01-01

Abstract

The aim of this trial was to compare the efficacy and safety of extended-release ciprofloxacin (CIPRO XR) versus the immediate-release formulation (CIPRO IR) in the treatment of complicated urinary tract infections (UTIs). 212 patients were randomized to CIPRO XR 1,000 mg tablet once daily or CIPROXIN IR 500 mg tablet twice daily. Treatment efficacy was evaluated by bacteriological outcome. Safety was measured by recording adverse events. The rate of bacteriological eradication was 83% in the CIPRO XR group and 75% in the CIPRO IR. the overall incidence of adverse events reported was higher in the CIPRO IR group. The authors conclude that CIPRO XR is a safe and effective treatment for complicated UTIs. Although the limited data available do not consent to support a statistically superior efficacy or safety compared to CIPRO IR, a trend in favor of CIPRO XR is clearly evident in all efficacy and safety variables. CIPRO XR is associated with reduced frequencies of drug-related adverse events compared to CIPRO IR.
2009
Settore MED/24 - Urologia
http://www.jchemother.it/cgi-bin/digisuite.exe/products?ID=154
MIRONE, V., FUSCO, F., TAGLIALATELA, D., VERZE, P., DI VITO, C., LOTTI, T., et al. (2009). Efficacy and safety of Cyprofloxacin XR 1000mg once daily versus Ciprofloxacin 500mg twice daily in the treatment of complicated urinary tract infections. JOURNAL OF CHEMOTHERAPY, 21(6), 651-660.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/54776
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 5
  • ???jsp.display-item.citation.isi??? ND
social impact